pI: 7.7933 |
Length (AA): 282 |
MW (Da): 30645 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_148443)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.16.1240 | cyclophilin 13, putative |
Leishmania donovani | LdBPK_161250.1 | cyclophilin, putative |
Leishmania infantum | LinJ.16.1250 | cyclophilin 13, putative |
Leishmania major | LmjF.16.1200 | cyclophilin 13, putative |
Leishmania mexicana | LmxM.16.1200 | cyclophilin, putative,PPIase, putative,rotamase, putative,peptidyl-prolyl cis-trans isomerase, putative |
Trypanosoma brucei gambiense | Tbg972.8.5140 | cyclophilin-type peptidyl-prolyl cis-trans isomerase, putative,PPIase, putative,rotamase, putative,cyclophilin, putative |
Trypanosoma brucei | Tb927.8.5230 | peptidyl-prolyl cis-trans isomerase, putative |
Trypanosoma congolense | TcIL3000_8_5070 | peptidyl-prolyl cis-trans isomerase, putative |
Trypanosoma cruzi | TcCLB.503581.20 | peptidyl-prolyl cis-trans isomerase, putative |
Trypanosoma cruzi | TcCLB.511217.120 | PPIase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.5230 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Plasmodium falciparum | peptidyl-prolyl cis-trans isomerase | 171 aa | 43.9% | 164 aa | Compounds | References |
Rattus norvegicus | Cyclophilin A | 164 aa | 41.9% | 167 aa | Compounds | References |
9 literature references were collected for this gene.